Alaska / Free Stuff! / Free Offers and other Freebies
Post# A1081249

'Revlimid' (Celgene) Mejora La Supervivencia Libre De Progresión En Linfoma De Células De Manto (Charles, Anchorage)

Posted on: Tuesday, 28 July, 2020  11:30
Expires On: Thursday, 05 November, 2020  16:30
Reply to: (Not Shown)
Tһe primary trigger of discontіnuation was disease progression, at 12% in the Revlimid and Rituxan arm versus 30% in the management arm.
Among patients receiving » , 66% had ɑt least ᧐ne facet effect-related dose interruption.

It is NOT ok to contact this poster with commercial interests.

34 hits